<DOC>
	<DOCNO>NCT01630967</DOCNO>
	<brief_summary>Men castrate resistant prostate cancer switch luteinizing hormone-releasing hormone ( LHRH ) antagonists LHRH agonist experience fall prostate-specific antigen ( PSA ) .</brief_summary>
	<brief_title>Efficacy Study Switching Lutenizing Hormone-releasing Hormone ( LHRH ) Antagonist From LHRH Agonist Treat Progressive Castrate Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description>To determine proportion patient castrate resistant Prostate Cancer PSA decline ≥50 % baseline PSA switch LHRH agonist LHRH antagonist .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologically confirm adenocarcinoma prostate currently receive LHRH agonist Antiandrogen oral therapy permit discontinue upon enrollment PSA &gt; 2 ng/ml rise PSA despite LHRH agonist patient may may clinical evidence metastasis . If metastasis present , must asymptomatic bone lymph node Prior chemotherapy allow ECOG performance status 01 Patients history active malignancy , except : adequately treat nonmelanoma skin cancer , superficial bladder cancer , solid tumour curatively treat evidence disease ≥ 3 year . Other serious illness , psychiatric medical condition would permit patient manage accord protocol include : ) Significant cardiovascular condition include limited : uncontrolled hypertension , unstable angina , significant congestive heart failure myocardial infarction , deep venous thrombosis , pulmonary embolus cerebrovascular attack within last 6 month . ii ) History significant neurological disorder would impair ability obtain consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>castrate resistance</keyword>
	<keyword>PSA progression</keyword>
	<keyword>LHRH antagonism</keyword>
</DOC>